The next generation sequencing technology, also known as NGS, is a massive sequencing machine that is also used to detect the targeted sequence of the RNA or DNA or understand the entire genome. For the coronavirus pandemic, NGS allowed comprehensive analysis of the SARS-CoV-2 virus, which researchers used to create the vaccines and the diagnosing assays. The first version of this technology was launched in the 2000s, and the company was later bought by Illumina . Although NGS can identify the viral agents without prior knowledge, it also creates a massive amount of data, costs more, and takes a long time to process .